Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma

NCT00116363 is registered in ClinicalTrials.gov with Introgen Therapeutics as lead sponsor.

NCT NCT00116363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma
Lead sponsor
Introgen Therapeutics
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2005
Completion date
December 31, 2006
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, neoplasm metastasis